SC
AVDL

Stempoint Capital’s Avadel Pharmaceuticals AVDL Stock Holding History

Stempoint Capital’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-223,660
Closed -$3.78M – 50
2024
Q1 		$3.78M Buy
+223,660
New +$3.33M 1% 31

Other funds holding AVDL

AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Stempoint Capital's AVDL Position: Q2 2024 in Review

Stempoint Capital sold out of Avadel Pharmaceuticals (AVDL) in Q2 2024, closing a stake of 223,660 shares — an estimated $3.78M sold.

Stempoint Capital first reported a position in AVDL in Q1 2024 and held it in 1 quarter. The position peaked at $3.78M in Q1 2024. 155 funds tracked by Wall St. Rank hold AVDL as of Q2 2024.

  • Stempoint Capital reported no remaining Avadel Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Stempoint Capital sold 223,660 Avadel Pharmaceuticals shares in Q2 2024, an estimated $3.78M.
  • Stempoint Capital first reported a position in Avadel Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Stempoint Capital's Avadel Pharmaceuticals position peaked at $3.78M in Q1 2024.
  • 155 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2024.

Based on Stempoint Capital's 13F filing for Q2 2024, filed 13 Aug 2024.